Adrian Kinkaid
Director Ejecutivo en FUSION ANTIBODIES PLC .
Fortuna: 22 058 $ al 30/04/2024
Perfil
Adrian Kinkaid is currently the Chief Executive Officer & Director at Fusion Antibodies Plc since 2022.
Prior to this, he was the Chief Executive Officer at MIP Discovery Ltd.
(United Kingdom) from 2015 to 2022.
Dr. Kinkaid holds a doctorate degree from The University of Southampton.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
FUSION ANTIBODIES PLC
0.57% | 14/02/2024 | 546 272 ( 0.57% ) | 22 058 $ | 30/04/2024 |
Cargos activos de Adrian Kinkaid
| Empresas | Cargo | Inicio |
|---|---|---|
| FUSION ANTIBODIES PLC | Director Ejecutivo | 15/08/2022 |
Antiguos cargos conocidos de Adrian Kinkaid.
| Empresas | Cargo | Fin |
|---|---|---|
MIP Discovery Ltd. (United Kingdom)
 MIP Discovery Ltd. (United Kingdom) Miscellaneous Commercial ServicesCommercial Services MIP Diagnostic Ltd. develops molecularly imprinted polymers for research purposes, diagnostics and drugs. The company was founded by Sergey Piletsky in 2015 and is headquartered in Leicester, the United Kingdom. | Director Ejecutivo | 15/08/2022 |
Formación de Adrian Kinkaid.
| The University of Southampton | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| FUSION ANTIBODIES PLC | Health Services |
| Empresas privadas | 1 |
|---|---|
MIP Discovery Ltd. (United Kingdom)
MIP Discovery Ltd. (United Kingdom) Miscellaneous Commercial ServicesCommercial Services MIP Diagnostic Ltd. develops molecularly imprinted polymers for research purposes, diagnostics and drugs. The company was founded by Sergey Piletsky in 2015 and is headquartered in Leicester, the United Kingdom. | Commercial Services |
- Bolsa de valores
- Insiders
- Adrian Kinkaid